We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+37.96%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.12B
AUM Growth
+$239M
Cap. Flow
+$117M
Cap. Flow %
10.4%
Top 10 Hldgs %
67.61%
Holding
75
New
17
Increased
14
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$58.1M
2
YMAB
Y-mAbs Therapeutics
YMAB
+$53.5M
3
SNY icon
Sanofi
SNY
+$17.6M
4
PBYI icon
Puma Biotechnology
PBYI
+$13.3M
5
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
+$12.4M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$14.6M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$9.46M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$8.96M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$8.8M
5
BLUE
bluebird bio
BLUE
+$8.69M

Sector Composition

Rank Sector Weight
1 Healthcare 85.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$176M 15.66%
2,479,514
– –
OBSV
2
DELISTED
ObsEva SA Ordinary Shares
OBSV
$85.6M 7.63%
4,749,623
– –
AMRN
3
Amarin Corp
AMRN
$284M
$84.7M 7.55%
260,415
+94,336
+57% +$7.12M
NTRA icon
4
Natera
NTRA
$37.5B
$74.2M 6.62%
3,100,560
– –
PRNB
5
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$59.6M 5.31%
+2,059,146
New +$58.1M
YMAB
6
DELISTED
Y-mAbs Therapeutics
YMAB
$55.9M 4.98%
+2,104,278
New +$53.5M
CHRS icon
7
Coherus Oncology
CHRS
$217M
$47.3M 4.22%
2,868,221
-25,000
-0.9% -$443K
MRUS
8
DELISTED
Merus
MRUS
$38.7M 3.45%
1,961,039
– –
BOLD
9
DELISTED
Audentes Therapeutics, Inc
BOLD
$37M 3.3%
933,640
– –
ONCE
10
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$26.3M 2.34%
481,270
– –
KNSA icon
11
Kiniksa Pharmaceuticals
KNSA
$4.83B
$23.5M 2.1%
922,700
– –
ACRS icon
12
Aclaris Therapeutics
ACRS
$730M
$22.4M 1.99%
1,539,480
– –
SNY icon
13
Sanofi
SNY
$104B
$18.4M 1.64%
+412,746
New +$17.6M
AGN
14
DELISTED
Allergan plc
AGN
$18.3M 1.63%
96,021
-15,529
-14% -$2.85M
NCNA
15
NuCana
NCNA
$5.37M
$16.6M 1.48%
133
– –
PBYI icon
16
Puma Biotechnology
PBYI
$406M
$15.4M 1.38%
336,835
+274,899
+444% +$13.3M
ETTX
17
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$12.8M 1.14%
+1,180,178
New +$12.4M
ITRM
18
DELISTED
Iterum Therapeutics
ITRM
$11.4M 1.02%
115,101
– –
RIGL icon
19
Rigel Pharmaceuticals
RIGL
$680M
$10.5M 0.93%
326,093
+98,820
+43% +$2.97M
APLS
20
DELISTED
Apellis Pharmaceuticals
APLS
$9.77M 0.87%
549,580
-66,222
-11% -$1.22M
AZN icon
21
AstraZeneca
AZN
$263B
$9.52M 0.85%
120,304
-44,596
-27% -$3.37M
HRTX icon
22
Heron Therapeutics
HRTX
$86.3M
$9.36M 0.83%
295,589
+37,004
+14% +$1.38M
ALXN
23
DELISTED
Alexion Pharmaceuticals
ALXN
$9.09M 0.81%
65,360
-75,392
-54% -$9.46M
TSRO
24
DELISTED
TESARO, Inc.
TSRO
$8.72M 0.78%
+223,675
New +$7.9M
SYBX
25
DELISTED
Synlogic
SYBX
$8.17M 0.73%
38,331
– –
1
2 3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2018 Portfolio in Review

As of Q3 2018, Sofinnova Investments held 75 positions worth $1.12B, up 27% from $883M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Sofinnova Investments deployed $117M of net new capital in Q3 2018, opening 17 new positions and adding to 14 existing holdings. Its largest new stake was Principia Biopharma Inc. Common Stock: 2,059,146 shares worth $59.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $9.46M trimmed.

  • Sofinnova Investments's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 2,059,146 shares worth $59.6M.
  • Sofinnova Investments added most to Puma Biotechnology in Q3 2018, an estimated $13.3M increase.
  • Sofinnova Investments's biggest Q3 2018 reduction was Alexion Pharmaceuticals, cutting an estimated $9.46M.
  • Sofinnova Investments fully exited Celgene Corp in Q3 2018, selling an estimated $14.6M.
  • Sofinnova Investments's ten largest holdings make up 68% of its $1.12B portfolio in Q3 2018.
  • Sofinnova Investments opened 17 new positions and closed 14 in Q3 2018.
  • Sofinnova Investments's portfolio value rose 27% quarter-over-quarter to $1.12B.

Based on Sofinnova Investments's 13F filing for Q3 2018, filed 15 Nov 2018.